Low-dose IL-2 promotes immune regulation in face transplantation: A pilot study.

[1]  A. Douiri,et al.  Low dose interleukin-2 selectively expands circulating regulatory T cells but fails to promote liver allograft tolerance in humans. , 2022, Journal of hepatology.

[2]  A. Bharat,et al.  Low‐dose IL‐2 prevents murine chronic cardiac allograft rejection: Role for IL‐2‐induced T regulatory cells and exosomes with PD‐L1 and CD73 , 2022, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  Shannan J. Ho Sui,et al.  Immunoregulatory and lipid presentation pathways are upregulated in human face transplant rejection. , 2021, The Journal of clinical investigation.

[4]  M. Gavin,et al.  An IL-2 mutein engineered to promote expansion of regulatory T cells arrests ongoing autoimmunity in mice , 2020, Science Immunology.

[5]  Jason D. Buenrostro,et al.  ImmGen at 15 , 2020, Nature Immunology.

[6]  James A. Hutchinson,et al.  Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials , 2020, The Lancet.

[7]  J. Bluestone,et al.  Treg cell-based therapies: challenges and perspectives , 2019, Nature Reviews Immunology.

[8]  B. Pomahac,et al.  Five-Year Follow-up after Face Transplantation. , 2019, The New England journal of medicine.

[9]  J. Todd,et al.  A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease , 2018, Journal of autoimmunity.

[10]  A. Loupy,et al.  Antibody-Mediated Rejection of Solid-Organ Allografts. , 2018, The New England journal of medicine.

[11]  M. Parkes,et al.  Mechanistic Sharing Between NK Cells in ABMR and Effector T Cells in TCMR , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  M. Sarwal,et al.  Polyclonal Regulatory T Cell Therapy for Control of Inflammation in Kidney Transplants , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[13]  I. Macdougall,et al.  IL-2 therapy restores regulatory T-cell dysfunction induced by calcineurin inhibitors , 2017, Proceedings of the National Academy of Sciences.

[14]  L. Riella,et al.  Treg‐Centric View of Immunosuppressive Drugs in Transplantation: A Balancing Act , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[15]  X. Jouven,et al.  Gene Expression Profiling for the Identification and Classification of Antibody-Mediated Heart Rejection , 2017, Circulation.

[16]  Hongye Liu,et al.  Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells. , 2016, JCI insight.

[17]  E. Morand,et al.  Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus , 2016, Nature Medicine.

[18]  J. Ritz,et al.  Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. , 2016, Blood.

[19]  Jeffrey A. Bluestone,et al.  Type 1 diabetes immunotherapy using polyclonal regulatory T cells , 2015, Science Translational Medicine.

[20]  R. Wiseman,et al.  Sequential Monitoring and Stability of Ex Vivo–Expanded Autologous and Nonautologous Regulatory T Cells Following Infusion in Nonhuman Primates , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[21]  R. Locksley,et al.  Interleukin-5-producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapy. , 2014, Blood.

[22]  Piero Carninci,et al.  Differential roles of epigenetic changes and Foxp3 expression in regulatory T cell-specific transcriptional regulation , 2014, Proceedings of the National Academy of Sciences.

[23]  J. Ritz,et al.  Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease , 2013, Science Translational Medicine.

[24]  A. Le Moine,et al.  Impact of interleukin-2-expanded regulatory T cells in various allogeneic combinations on mouse skin graft survival. , 2012, Transplantation proceedings.

[25]  A. Kirk,et al.  Regulatory T Cells Exhibit Decreased Proliferation but Enhanced Suppression After Pulsing With Sirolimus , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  T. Strom,et al.  Prolonged Survival of Allogeneic Islets in Cynomolgus Monkeys After Short‐Term Triple Therapy , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[27]  F. Carrat,et al.  Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. , 2011, The New England journal of medicine.

[28]  J. Ritz,et al.  Interleukin-2 and regulatory T cells in graft-versus-host disease. , 2011, The New England journal of medicine.

[29]  P. Halloran,et al.  Diagnosing Rejection in Renal Transplants: A Comparison of Molecular‐ and Histopathology‐Based Approaches , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[30]  J. Sprent,et al.  In vivo expansion of T reg cells with IL-2–mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression , 2009, The Journal of experimental medicine.

[31]  I. Türbachova,et al.  DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3+ conventional T cells , 2007, European journal of immunology.

[32]  V. Kuchroo,et al.  Contrasting Effects of Cyclosporine and Rapamycin in De Novo Generation of Alloantigen‐Specific Regulatory T Cells , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[33]  D. Valmori,et al.  Rapamycin-Mediated Enrichment of T Cells with Regulatory Activity in Stimulated CD4+ T Cell Cultures Is Not Due to the Selective Expansion of Naturally Occurring Regulatory T Cells but to the Induction of Regulatory Functions in Conventional CD4+ T Cells1 , 2006, The Journal of Immunology.